Previous 10 | Next 10 |
Sydney, Australia (ABN Newswire) - In this segment of The Ellis Martin Report, Ellis speaks with Jerome Jabbour, the CEO of Matinas Biopharma (NYSE:MTNB). The company announced a research collaboration with ViiV Healthcare to evaluate formulation of antiviral drug candidates. Additionally, Mr...
Matinas BioPharma ( MTNB -0.3% ) inks a research collaboration agreement with ViiV Healthcare under which the latter will explore the use of the former's lipid nano-crystal (LNC) platform delivery technology in developing new antivirals. More news on: Matinas BioPharma Holdings, Inc....
BEDMINSTER, N.J., May 15, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that they have entered into a research collaboration with ViiV Healthcare, a global specialist HIV company established in November of 2009 by GlaxoSmithKline (LSE: GSK)...
Matinas BioPharma Holdings, Inc. Q1 2019 Earnings Conference Call May 14, 2019 8:30 AM Company Participants Jenene Thomas - IR Jerry Jabbour - Chief Executive Officer Conference Call Participants Robert Hazlett - BTIG Presentation Operator Greetings and welcome to ...
BEDMINSTER, N.J., May 14, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended March 31, 2019 and provided an update on its corporate activities and product pi...
BEDMINSTER, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 14, 2019 at 8:30 a.m. ET to discuss oper...
BEDMINSTER, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has been invited to ring the NYSE Opening Bell® on Monday, May 6 th , 2019 at 9:30 AM E.T., to commemorate a tr...
BEDMINSTER, N.J., May 01, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Theresa Matkovits, Ph.D., Chief Development Officer of the Company, was selected to present a corporate overview an...
Sydney, Australia (ABN Newswire) - Join Ellis Martin for a conversation with Jerome Jabbour, CEO and Director of Matinas Biopharma, (NYSE:MTNB). Matinas BioPharma proprietary, disruptive technology utilizes a lipid nano-crystal (LNC) platform technology which can encapsulate small molecule dr...
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2018 Earnings Conference Call April 2, 2019 08:00 AM ET Company Participants Jenene Thomas - IR Jerry Jabbour - CEO Raphael Mannino - CSO James Ferguson - Chief Medical Officer Theresa Matkovits - Chief Development Officer Keith ...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focu...
BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report fi...
BEDMINSTER, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its or...